Regulatory decisions
134 filings were classified as regulatory decision in the last 90 days. The most recent was Aldeyra Therapeutics, Inc. (ALDX) on Nov 9, 2026.
Latest filings
| Filed | Issuer | Event | Classified excerpt | Source |
|---|---|---|---|---|
| ALDXAldeyra Therapeutics, Inc. | Regulatory decision | “In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations.” | 8-K ↗ | |
| NVCRNovoCure Limited | Regulatory decision | “NovoCure announced that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application.” | 8-K ↗ | |
| No ticker CIK 0001440799 | Regulatory decision | “Effective October 30, 2026, Pecos UltraClean Refining, LLC, a project affiliate of MMEX Resources Corporation (the "Company"), received notification from the Texas Commission on Environmental Quality ("TCEQ") approving the Permit by Rule registration application for the proposed UltraClean Refinery North facility located in Pecos County, Texas.” | 8-K ↗ | |
| No ticker CIK 0001445815 | Regulatory decision | “On November 4, 2026, the Company issued a press release entitled: “Bioxytran Secures Attested Free Sale Certification for A-SUQAR®, Opening the Path to the UAE and Gulf Markets.” | 8-K ↗ | |
| HZOMarineMax, Inc. | Regulatory decision | “As of October 31, 2026, all regulatory approvals and clearances required to consummate the Merger have been obtained and all applicable regulatory waiting periods have expired or been terminated.” | 8-K ↗ | |
| ICUSeaStar Medical Holding Corporation | Regulatory decision | “On November 3, 2026, the Company issued a press release announcing that the United States Food and Drug Administration has determined that the QUELIMMUNE Pediatric SAVE Surveillance Registry ("SAVE Registry") has fulfilled post-approval study requirements as outlined in the original Humanitarian Device Exemption approval of QUELIMMUNE.” | 8-K ↗ | |
| No ticker CIK 0001309082 | Regulatory decision | “On October 28, 2026, VOT received formal notification from LNE confirming the issuance of Attestation of Conformity No. 41506-0 for the VKIN 300 SD disinfection pretreatment unit. The Attestation confirms that the equipment complies with French Standard NF X 30-503-1:2024 and the applicable French regulatory framework governing the pretreatment by disinfection of infectious healthcare waste.” | 8-K ↗ | |
| AEONAEON Biopharma, Inc. | Regulatory decision | “On September 30, 2026, the Company publicly announced that it had received Type 2b meeting minutes from the U.S. Food and Drug Administration that did not preclude advancement of ABP-450 toward a Biologics License Application under the Section 351(k) biosimilar pathway, thereby triggering the accelerated expiration of the Two-Year Warrants in accordance with their terms.” | 8-K ↗ | |
| QUREuniQure N.V. | Regulatory decision | “the FDA has accepted for review the Biologics License Application ("BLA") for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington's disease submitted under the Accelerated Approval pathway.” The application “has been granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date of May 1, 2027.” | 8-K ↗ | |
| INOInovio Pharmaceuticals, Inc. | Regulatory decision | “On October 30, 2026, the Company announced that the FDA has granted accelerated approval for VOCERYQ™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce the frequency of surgery in adults with RRP.” | 8-K ↗ | |
| NRXPNRX Pharmaceuticals, Inc. | Regulatory decision | “On October 30, 2026, NRx Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments ("GDUFA").” | 8-K ↗ | |
| AESAES Corporation | Regulatory decision | “On October 28, 2026, the European Commission closed its preliminary review of the Merger in accordance with Article 10(4) of Regulation (EU) 2022/2560 ... (the "EU Foreign Subsidies Regulation Approval"). The EU Foreign Subsidies Regulation Approval is a condition to the closing of the Merger, which remains subject to certain additional regulatory approvals and other customary closing conditions.” | 8-K ↗ | |
| PVLAPalvella Therapeutics, Inc. | Regulatory decision | “On October 28, 2026, Palvella Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has accepted for filing and granted Priority Review to the Company's New Drug Application for QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations. The FDA has assigned a Prescription Drug User Fee Act target action date of February 28, 2027.” | 8-K ↗ | |
| No ticker CIK 0001115864 | Regulatory decision | “Since early 2026, OFAC has issued general licenses authorizing certain activities in the Venezuelan energy sector, including General License No. 48D (September 28, 2026).” | 8-K ↗ | |
| CPIXCumberland Pharmaceuticals Inc | Regulatory decision | “The Company announced plans to submit a New Drug Application ("NDA") to the U.S. Food and Drug Administration (the "FDA") for ifetroban as a treatment for the cardiomyopathy associated with DMD. Following the meeting the FDA granted the Company's request for rolling review of the NDA, which allows completed sections of the application to be provided to the FDA for review, before the full application is submitted.” | 8-K ↗ | |
| PHATPhathom Pharmaceuticals, Inc. | Regulatory decision | “The litigation was brought to challenge FDA's June 6, 2025 decision granting Phathom's Citizen Petition, which agreed with Phathom that VOQUEZNA benefits from 10 years of New Chemical Entity ("NCE") exclusivity through May 3, 2032.” | 8-K ↗ | |
| MIRMMirum Pharmaceuticals, Inc. | Regulatory decision | “The results build on data from PROGRESS Cohort 1, which supported the U.S. Food and Drug Administration approval of ATEBRIOZ in September 2026 for adult and pediatric patients aged 12 years and older with FOP.” | 8-K ↗ | |
| PHATPhathom Pharmaceuticals, Inc. | Regulatory decision | “Phathom believes that FDA carefully and correctly evaluated this issue in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition, in which FDA recognized 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.” | 8-K ↗ | |
| SUPNSupernus, Inc. | Regulatory decision | “The Company issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The seven-year market exclusivity for ONAPGO began on February 3, 2025, the date of FDA approval.” | 8-K ↗ | |
| CGTXCognition Therapeutics, Inc. | Regulatory decision | “On October 22, 2026, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing the receipt of written feedback from the U.S. Food and Drug Administration (the "FDA") confirming alignment on key elements of a Phase 3 study in dementia with Lewy bodies.” | 8-K ↗ | |
| ABUSArbutus Biopharma Corporation | Regulatory decision | “On October 22, 2026, Arbutus Biopharma Corporation (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company's oral PD-L1 inhibitor.” | 8-K ↗ | |
| AARDAardvark Therapeutics, Inc. | Regulatory decision | “On October 22, 2026, Aardvark Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration lifted the clinical hold on the Company's Investigational New Drug application for ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome.” | 8-K ↗ | |
| BHVNBiohaven Ltd. | Regulatory decision | “The FDA has informed Biohaven that the company's new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review. The FDA communicated that it considers the resubmission a complete response to the November 4, 2025 action letter, and has assigned a user fee goal date in the first quarter of 2027.” | 8-K ↗ | |
| IONSIonis Pharmaceuticals, Inc. | Regulatory decision | “Ionis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of chronic hepatitis B virus infection in combination with NrtI therapy in specified adult patients without cirrhosis.” | 8-K ↗ | |
| DVDoubleVerify Holdings, Inc. | Regulatory decision | “On October 5, 2026, the Merger received clearance from the German Federal Cartel Office (Bundeskartellamt). On October 7, 2026, the Merger received clearance from the Commission for the Protection of Competition of the Republic of Cyprus. On October 13, 2026, the Merger received clearance from the ACCC... Also on October 13, 2026, the Merger received clearance from the Moroccan Competition Council.” | 8-K ↗ |
GET /stocks/filings/8-K/vX/disclosures?tertiary_category=regulatory_decision&filing_date.gte=2026-08-12&sort=filing_date.desc&limit=1000Each category is a separate request; rows are merged and de-duplicated by filing.
{
"status": "OK",
"results": [
{
"tickers": [
"NVCR"
],
"cik": "0001645113",
"accession_number": "0001645113-26-000085",
"filing_date": "2026-11-09",
"primary_category": "operations_and_strategy",
"secondary_category": "business_developments",
"tertiary_category": "regulatory_decision",
"supporting_text": "NovoCure announced that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application.",
"filing_url": "https://www.sec.gov/Archives/edgar/data/1645113/0001645113-26-000085.txt"
},
{
"tickers": [
"ALDX"
],
"cik": "0001341235",
"accession_number": "0001193125-26-453537",
"filing_date": "2026-11-09",
"primary_category": "operations_and_strategy",
"secondary_category": "business_developments",
"tertiary_category": "regulatory_decision",
"supporting_text": "In June 2023, we received a Complete Response Letter for our New Drug Application (\"NDA\") for ADX-2191 for the treatment of primary vitreoretinal lymphoma (\"PVRL\"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations.",
"filing_url": "https://www.sec.gov/Archives/edgar/data/1341235/0001193125-26-453537.txt"
}
]
}
// trimmed to 2 resultsWhat these filings mean
- Regulatory decision
- Regulatory approvals, rejections, complete response letters, or information requests from FDA, EPA, or other agencies.
How this page works
- Every 8-K disclosure from the last 90 days is classified, and those in the categories above are listed here.
- One row per filing: a filing in several categories appears once.
- Labels are assigned automatically from the filing text, so always check the linked 8-K.
Other 8-K events
- Listing deficiency & delisting notices
- CEO departures
- CFO & executive departures
- Stock splits
- Merger agreements & completions
- Share buyback programs
- Dividend declarations
- Earnings releases
- Guidance updates
- Clinical trial results
- Bankruptcy filings
- Financial restatements
- Auditor changes
- Cybersecurity incidents
- Layoffs & restructuring
Frequently asked questions
What is an SEC Form 8-K?
An 8-K is how a public company tells investors about a major event between its quarterly reports. Companies usually have four business days to file one.
How recent is this regulatory decisions list?
It covers 8-K filings from the last 90 days, classified as regulatory decisions and sorted newest first. The Massive 8-K disclosures API has the full, continuously updated record.
Build with AI
Track these filings with your agent
This page is built from the Massive 8-K disclosures endpoint. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check the 8-K disclosures endpoint once a day for new filings classified as regulatory decisions (query tertiary_category=regulatory_decision) and tell me about each new one, with the company, filing date, excerpt and SEC link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.